OncoMatch/Clinical Trials/NCT05401110
Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer
Is NCT05401110 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including Osimertinib and Carotuximab for non small cell lung cancer.
Treatment: Osimertinib · Carotuximab — The purpose of this study is to examine the combination of osimertinib and carotuximab to assess the safety and find the recommended dose for treatment of advanced EGFR-mutated non-small cell lung cancer (NSCLC). Safety and tolerability will be measured by the number of dose-limiting toxicities, according to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Version 5, to find the maximum tolerated dose. The secondary objectives include evaluating the rate of objective response rate, duration of response, progression-free survival, and disease control rate, along with assessing biomarkers through tumor tissue and circulating tumor DNA.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR exon 19 deletion
Required: EGFR g719x
Required: EGFR l858r
Required: EGFR l861q
Disease stage
Required: Stage IV
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: EGFR tyrosine kinase inhibitor
Part I: Progressive disease on at least one prior EGFR TKI
Cannot have received: CD105 targeted antibody (carotuximab)
Prior exposure to carotuximab or any CD105 targeted antibody
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Cedars-Sinai Cancer at Beverly Hills (THO) · Beverly Hills, California
- Cedars-Sinai Cancer at The Angeles Clinic and Research Institute · Los Angeles, California
- Cedars-Sinai Cancer at SOCC · Los Angeles, California
- Cedars-Sinai Medical Center · Los Angeles, California
- Cedars-Sinai Cancer at Hunt Cancer Center - TMPNCC · Torrance, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05401110 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior CD105 targeted antibody disqualifies patients from enrollment.
Does this trial require EGFR?
Yes, EGFR exon 19 deletion is a required biomarker for enrollment.
Does this trial require EGFR?
Yes, EGFR g719x is a required biomarker for enrollment.
Does this trial require EGFR?
Yes, EGFR l858r is a required biomarker for enrollment.
What disease stage is eligible?
Stage IV is required (metastatic disease required).
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify